December 19, 2024 10:13 AM EST

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal.

The large drugmaker

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's